ABC008-IBM-201: A Phase II/III Randomized Double-blind Placebo-controlled Multicenter

Build status - In Progress

Recruiting

99 years or below

All

1 Location

Brief description of study

dosing of ABC008 in subjects with inclusion body myositis (IBM).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 08 Mar 2023. Study ID: 853035

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

View email

Phone

View phone

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center

ABC008-IBM-201: A Phase II/III Randomized Double-blind Placebo-controlled Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis

Brief description of study

Eligibility of study

Find a site

Interested in the study